Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitravatinib (Primary) ; Tislelizumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors BeiGene

Most Recent Events

  • 10 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 09 Aug 2022 Results (n=24; Between May 12, 2020 and February 10, 2021; data cut-off November 8, 2021) assessing safety, tolerability, and antitumor activity of sitravatinib and tislelizumab in patients with programmed death-ligand 1 positive, squamous non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
  • 09 Aug 2022 Results (n=22) assessing results from patients with programmed death-ligand 1 positive, non-squamous non-small cell lung cancer , presented at the 2022 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top